FDA approves Moderna's mRNA flu vaccine, the first to use the technology
The Food and Drug Administration has approved Moderna's mFlusiva, the first influenza vaccine built on messenger RNA (mRNA) technology, extending a platform that was administered billions of times worldwide during the Covid-19 pandemic into the realm of seasonal flu prevention.
Conventional flu vaccines are typically produced over several months using egg-based manufacturing and rely on the World Health Organization's forecast of which viral strains will circulate that season. mRNA technology can compress that production timeline to weeks, allowing formulations to be updated more quickly if predictions shift.
In clinical trials, mFlusiva showed an immune response at least equivalent to traditional vaccines, and stronger results in some age groups. Moderna presented data to the FDA indicating the vaccine produced a notably robust immune response in older adults, a population that often responds less well to standard flu shots.
Experts say the approval's significance extends beyond efficacy numbers. The flexibility of the mRNA platform strengthens the case for future combination vaccines targeting both flu and Covid-19; Moderna has already disclosed it is developing such a combined shot.
On safety, regulators noted that monitoring should continue for myocarditis, a rare side effect observed with mRNA Covid-19 vaccines. The FDA said post-approval surveillance studies would help clarify the scale of that risk in the flu vaccine context.
Health economists expect that manufacturing costs for mRNA-based flu vaccines may initially exceed those of conventional shots, though the gap could narrow as production scales up. Insurance coverage and pricing decisions will heavily influence how quickly the vaccine reaches wide use.
Vaccine specialists say the biggest advantage of mRNA technology is its capacity for rapid response. When a new flu strain emerges, updating the formulation can happen far faster than with traditional manufacturing methods.
The approval has also reignited discussion among health officials about pandemic preparedness. Some experts argue that expanding mRNA technology into seasonal flu means manufacturing infrastructure will be better positioned if another pandemic emerges.
Moderna plans to release mFlusiva in limited quantities this coming autumn season, with production scaling gradually over subsequent years. Company officials acknowledge it will likely take years before the vaccine fully displaces conventional formulations.
Experts expect patients and doctors will be able to choose between conventional and mRNA-based flu vaccines during this transition period, though many anticipate the mRNA platform could eventually become the standard for seasonal flu protection.
Read next
The moment an earthquake shook a Japanese hospital mid-operation, and what it reveals about disaster-ready care
Security camera footage from Kumamoto General Hospital shows surgeons shielding a patient on the operating table as a magnitude 6.8 earthquake shook the building last month. The video has renewed attention on how hospitals in seismically active regions design operating rooms, staff protocols and building infrastructure to keep surgery safe during a disaster.
FDA approves Bristol Myers Squibb drug, marking debut of a new class for blood cancer
The US Food and Drug Administration has approved a Bristol Myers Squibb treatment, marketed as Zenbexus, for advanced multiple myeloma, introducing a new class of drugs for the incurable blood cancer. The approval offers another option for patients whose disease has stopped responding to existing therapies.
Can antihistamines really ease PMDD and menopause symptoms
A social media trend claims that combining two over-the-counter antihistamines, Allegra and Pepcid, can dramatically ease the emotional and physical symptoms of premenstrual dysphoric disorder and menopause. Doctors say there is a plausible biological mechanism involving mast cells and hormones, but caution that the evidence remains thin and self-medicating carries real risks.
Iceberg, romaine or kale: which salad greens are actually the healthiest
Nutritionists say not all salad greens are created equal: darker, more bitter leaves generally carry more vitamins, minerals and fiber than pale, watery ones like iceberg lettuce. Here is how the most common options compare, and what actually matters when building a healthy salad.
Triple-drug treatment clears HIV in newborn primates within days of exposure
Researchers used a one-time combination of three therapies — standard antiretrovirals, broadly neutralizing antibodies and an experimental antibody — to completely clear HIV from newborn nonhuman primates treated within three days of exposure. None of the three treatments cleared the virus alone, suggesting a narrow but real window for eliminating infection soon after birth.